Fulgent Genetics, Inc. FLGT
Set alert
As of Nov 2, 10:45 AM ET
- YTD
- -23.89%
- 1 year
- -10.94%
- Open
- 20.82
- Prev close
- 20.62
- Mkt cap
- 552.50M
- Vol
- 48.08K
- Avg vol
- 288.42K
- EPS
- -2.82
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 19.93
- High
- 20.84
- Forward P/E
- -36.45
- Beta
- 1.51
- Short ratio
- 2.87
- Inst. own
- 54.30%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 19.48
- 200-d avg
- 21.08
- 1y target
- 27.67
News
2 weeks ago defenseworld.net
Head to Head Survey: Agilon Health (NYSE:AGL) and Fulgent Genetics (NASDAQ:FLGT)
Fulgent Genetics (NASDAQ: FLGT - Get Free Report) and Agilon Health (NYSE: AGL - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two…
2 weeks ago businesswire.com
Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a…
1 month ago defenseworld.net
Corient Private Wealth LP Lowers Stake in Fulgent Genetics, Inc. $FLGT
Corient Private Wealth LP cut its stake in Fulgent Genetics, Inc. (NASDAQ: FLGT) by 34.8% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission…
1 month ago zacks.com
PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?
Precipio and Fulgent Genetics differ in business scope, valuation and growth drivers, but which cancer diagnostics stock looks more compelling now? Let's dive in.
2 months ago defenseworld.net
Hsbc Holdings PLC Purchases New Position in Fulgent Genetics, Inc. $FLGT
Hsbc Holdings PLC purchased a new stake in shares of Fulgent Genetics, Inc. (NASDAQ: FLGT) in the second quarter, according to the company in its most recent filing with the SEC. The fund purchased…
-
3 months ago benzinga.com
Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $19
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and raises the price target from $15 to $19.
3 months ago seekingalpha.com
Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript
Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript
3 months ago benzinga.com
Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures rise, Nasdaq 100 up 300 points. Apple Inc shares fall 7.4% despite beating analyst estimates for Q3. Other stocks also dip in pre-market.
3 months ago marketbeat.com
Fulgent Genetics Q2 Earnings Call Highlights
Fulgent Genetics NASDAQ: FLGT reported second-quarter 2026 revenue of $85.4 million, up 20% sequentially and 4% from a year earlier, as the company incorporated a full quarter of contributions from…
3 months ago zacks.com
Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Misses Revenue Estimates
Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to earnings of $0.07 per share a year ago.
3 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's after-market session. The market value of their outstanding shares is at $297.1 million. uniQure…
-
3 months ago benzinga.com
Fulgent Genetics Lowers FY2026 Adj EPS Guidance from $(1.59) to $(2.35)-$(2.22) vs $(1.55) Est; Lowers FY2026 Sales Guidance from $350.000M to $330.000M-$340.000M vs $351.900M Est
Fulgent Genetics (NASDAQ:FLGT) lowers FY2026 Adj EPS guidance from $(1.59) to $(2.35)-$(2.22) vs $(1.55) analyst estimate. Lowers FY2026 sales outlook from $350.000 million to $330.000…
-
3 months ago benzinga.com
Fulgent Genetics Q2 Adj. EPS $(0.58) Misses $(0.46) Estimate, Sales $85.389M Miss $94.000M Estimate
Fulgent Genetics (NASDAQ:FLGT) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.46) by 26.09 percent. This is a 928.57 percent decrease over earnings…
3 months ago businesswire.com
Fulgent Reports Second Quarter 2026 Financial Results
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a…
3 months ago seekingalpha.com
Fulgent Genetics: Strong Moves By Management Keep Me Bullish
Fulgent Genetics remains a long-term play, supported by a strong balance sheet and disciplined capital allocation. Recent opportunistic share repurchases at $15.42/share and insider buying highlight…
3 months ago businesswire.com
Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a…
5 months ago businesswire.com
Fulgent Presents Updated FID-007 Data at ASCO 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with established laboratory services and therapeutic development…
5 months ago globenewswire.com
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. (“Fulgent” or the…
-
5 months ago benzinga.com
Fulgent Genetics' FID-007 Plus Cetuximab Shows 60% Response Rate And 7.2-Month Median PFS In Phase 2 Head And Neck Cancer Study With Favorable Safety Profile
Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today…
5 months ago businesswire.com
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a…
5 months ago globenewswire.com
Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fulgent Genetics, Inc. (NASDAQ: FLGT). The investigation focuses on…
5 months ago globenewswire.com
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. (“Fulgent” or the…
-
6 months ago benzinga.com
Piper Sandler Reiterates Neutral on Fulgent Genetics, Lowers Price Target to $15
Piper Sandler analyst David Westenberg reiterates Fulgent Genetics (NASDAQ:FLGT) with a Neutral and lowers the price target from $30 to $15.
6 months ago businesswire.com
Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics
BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)--FoundationOne®PGx helps guide cancer therapy selection and dosing strategies to support safer, more effective patient care.
6 months ago seekingalpha.com
Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript
Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript
6 months ago benzinga.com
Full Transcript: Fulgent Genetics Q1 2026 Earnings Call
Full Transcript: Fulgent Genetics Q1 2026 Earnings Call
6 months ago zacks.com
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Beats Revenue Estimates
Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to earnings of $0.04 per share a year ago.
6 months ago businesswire.com
Fulgent Reports First Quarter 2026 Financial Results
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a…
8 months ago benzinga.com
Nasdaq Down Over 1%; Dell Shares Jump After Q4 Results
U.S. stocks down mid-trading, Nasdaq falls 1%. Dow down 1.40%, S&P 500 falls 0.74%. Dell shares up 21% on Q4 earnings.
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
8 months ago benzinga.com
Dow Dips Over 600 Points; US Producer Prices Increase In January
US stocks traded lower, Dow down 600 points. Nasdaq and S&P also fell. Consumer staples up, tech down. Producer prices rose in January.
-
8 months ago benzinga.com
Fulgent Genetics Sees FY2026 Adj EPS $(1.45) vs $(0.32) Est; Sees Sales $350.000M vs $356.333M Est
Fulgent Genetics (NASDAQ:FLGT) is looking for FY2026 Adj EPS of $(1.45) vs $(0.32) analyst estimate. sees sales of $350.000 million vs $356.333 million analyst estimate.
8 months ago benzinga.com
Fulgent Genetics Q4 Earnings Assessment
Fulgent Genetics Q4 Earnings Assessment
-
8 months ago benzinga.com
Fulgent Genetics Q4 Adj. EPS $0.16 Beats $0.03 Estimate, Sales $83.336M Miss $85.381M Estimate
Fulgent Genetics (NASDAQ:FLGT) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.03 by 433.33 percent. This is a 300 percent increase over earnings of…
-
8 months ago benzinga.com
Earnings Scheduled For February 27, 2026
Earnings Scheduled For February 27, 2026
-
11 months ago benzinga.com
Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $30
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and raises the price target from $21 to $30.
-
12 months ago benzinga.com
Fulgent Genetics Raises FY2025 GAAP EPS Guidance from $(2.10) to $(1.70) vs $(1.94) Est
Fulgent Genetics (NASDAQ:FLGT) raises FY2025 GAAP EPS guidance from $(2.10) to $(1.70) vs $(1.94) analyst estimate..
-
12 months ago benzinga.com
Fulgent Genetics Raises FY2025 Adj EPS Guidance from $(0.35) to $0.30 vs $(0.35) Est; Raises FY2025 Sales Guidance from $320.000M to $325.000M vs $320.118M Est
Fulgent Genetics (NASDAQ:FLGT) raises FY2025 Adj EPS guidance from $(0.35) to $0.30 vs $(0.35) analyst estimate. Raises FY2025 sales outlook from $320.000 million to $325.000 million vs $320.118…
-
12 months ago benzinga.com
Fulgent Genetics Q3 Adj. EPS $0.14 Beats $(0.22) Estimate, Sales $84.069M Beat $81.431M Estimate
Fulgent Genetics (NASDAQ:FLGT) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $(0.22) by 162.78 percent. This is a 54.84 percent decrease over earnings of…
12 months ago benzinga.com
Earnings Scheduled For November 7, 2025
Earnings Scheduled For November 7, 2025
-
1 year ago benzinga.com
Fulgent Genetics Reports Phase 2 Cancer Drug Results Ahead Of ESMO 2025 Presentation
Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today…
-
1 year ago benzinga.com
UBS Upgrades Fulgent Genetics to Buy, Raises Price Target to $30
UBS analyst Lu Li upgrades Fulgent Genetics (NASDAQ:FLGT) from Neutral to Buy and raises the price target from $20 to $30.
-
1 year ago benzinga.com
Piper Sandler Maintains Neutral on Fulgent Genetics, Lowers Price Target to $21
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and lowers the price target from $23 to $21.
1 year ago benzinga.com
Monolithic Power Systems, Workiva, Interface, AppFolio And Other Big Stocks Moving Higher On Friday
Monolithic Power Systems, Workiva, Interface, AppFolio And Other Big Stocks Moving Higher On Friday
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
1 year ago benzinga.com
Fulgent Genetics Raises FY2025 Adj EPS Guidance from $(0.65) to $(0.35) vs $(0.55) Est; Raises FY2025 Sales Guidance from $310.000M to $320.000M vs $310.682M Est
Fulgent Genetics (NASDAQ:FLGT) raises FY2025 Adj EPS guidance from $(0.65) to $(0.35) vs $(0.55) analyst estimate. Raises FY2025 sales outlook from $310.000 million to $320.000 million vs $310.682…
-
1 year ago benzinga.com
Fulgent Genetics Q2 Adj. EPS $0.07 Beats $(0.18) Estimate, Sales $81.803M Beat $76.205M Estimate
Fulgent Genetics (NASDAQ:FLGT) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0.18) by 138.25 percent. This is a 53.33 percent decrease over earnings of…